N/A N=43 Randomized Treatment

Detection of Plaque Inflammation by Positron Emission Tomography (PET)-Effects of Simvastatin on Plaque Inflammation

Atherosclerosis

Bottom Line

View on ClinicalTrials.gov: NCT00114504 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2015

Primary outcome: Primary: Plaque Inflammation — 1.59; 1.63 SUV

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: simvastatin (Drug)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: Kurume University
Primary completion: Apr 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Plaque Inflammation	1.59; 1.63	—
SECONDARY Circulating Inflammation Marker	0.09; 0.06; 0.11; 0.07	—

Summary

The purpose of this study is to determine whether FDG-PET is capable of detecting atherosclerotic plaque inflammation and monitoring the effects of statins on plaque inflammation. The usefulness of FDG-PET in risk stratification is also investigated.

Eligibility Criteria

Inclusion Criteria

Protocol 1: patients who had carotid atherosclerosis detected by carotid ultrasound.
Protocol 2: patients who underwent FDG-PET for cancer screening and had vascular FDG uptakes

Exclusion Criteria

Active inflammatory diseases
Dyslipidemia under medications
Uncontrolled diabetes mellitus, vasculitis, symptomatic coronary artery disease, symptomatic cerebrovascular diseases
Known systemic disorders such as hepatic, renal, hematopoietic, and malignant diseases

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00114504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.